Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Skin

25th Feb 2026

ADACCESS trial results comparing GP2017 (adalimumab biosimilar) and reference adalimumab treatments for plaque psoriasis: a plain language summary

22nd Jan 2026

Plain language summary: EASE research on Oleogel-S10 birch bark extract in epidermolysis bullosa care

15th Sep 2025

Evaluating an OX40 ligand-blocking antibody for eczema treatment in the STREAM-AD clinical trial: a plain language summary

16th Jul 2025

Plain language summary: measuring patient satisfaction with hair regrowth results from ritlecitinib treatment

23rd Apr 2025

Plain language summary of a review on omalizumab for treating chronic spontaneous urticaria

22nd Apr 2025

Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study

Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. Encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma. Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group).
20th Jun 2023

Encorafenib and binimetinib for people with BRAF V600-mutant melanoma, 5-year update of the COLUMBUS study- Plain Language Summary

Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body’s defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD
2nd Jun 2023

Plain Language Summary: comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered by scales. This can cause the skin to itch, crack or bleed, and the associated itching and pain can make it difficult to perform basic everyday tasks. Living with psoriasis can cause emotional distress. Treatments are available, but some do not always reduce the symptoms of psoriasis, some may need to be injected or taken multiple times a day, and some may have side effects. Researchers are looking for new treatments that are more effective, convenient to take, and have acceptable safety and tolerability.
23rd May 2023

Plain Language Summary: POETYK PSO-1 study, treatment of plaque psoriasis with deucravacitinib

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis. Plaque psoriasis appears on the body as dry, discolored, patches of skin that can be flaky and covered in scales. This can make the skin itch, crack or bleed and make it difficult for people with psoriasis to perform basic everyday tasks. Treatments are available, but some do not always reduce symptoms or may need to be injected or taken multiple times a day, which can be difficult to do, or can have undesirable side effects. Researchers are looking for new treatments for psoriasis
23rd May 2023

Plain Language Summary: treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study)

11th Apr 2023

Plain Language Summary: the development and validation of risk calculators for people with “thin” melanomas on their skin to predict the likelihood that their cancer will return

17th Jun 2022

Spesolimab treatment for people with flares of generalized pustular psoriasis: a plain language summary of the Effisayil™ 1 study

15th Nov 2021

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy